Inloggen
E-mail
Wachtwoord
Paswoord weergeven
Bewaren
Bent u uw wachtwoord vergeten?
Gratis lid worden
Registreer
Registreer
Instellingen
Instellingen
Dynamische koersen 
OFFON

PROTAGONIST THERAPEUTICS, INC.

(PTGX)
OverzichtKoersenGrafiekenNieuwsRatingsAgendaOndernemingFinanciŽnConsensusHerzieningenBeursproducten 
OverzichtAl het nieuwsAanbevelingen van analistenAndere talenPersberichtenOfficiŽle publicatiesSectornieuws
Communiquťs de presse de la sociťtť PROTAGONIST THERAPEUTICS, INC.
03/12Protagonist Therapeutics to Present at the JMP Securities Hematology and Oncology Summi..
PR
02/12Protagonist Therapeutics Announces the Selection of Oral Peptide PN-235 into Phase 2 Cl..
PR
16/11Protagonist Therapeutics Announces Positive Phase 2a Data Supporting the Potential Use ..
AQ
11/11Protagonist Therapeutics to Participate in Two Upcoming Healthcare Investor Conferences
PR
05/11Protagonist Therapeutics Announces Updated Data from Phase 2 Study of Rusfertide in Pol..
AQ
03/11PROTAGONIST THERAPEUTICS : Q3 Earnings Snapshot
AQ
03/11PROTAGONIST THERAPEUTICS, INC MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDIT..
AQ
03/11Protagonist Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corp..
PU
26/10Protagonist Therapeutics Earns $7.5 Million Milestone Payment from IL-23 Receptor Colla..
PR
12/10PROTAGONIST THERAPEUTICS : to Present at the Jefferies Next Generation IBD Therapeutics Su..
PR
11/10PROTAGONIST THERAPEUTICS : Announces Removal of FDA Clinical Hold on the Rusfertide Clinic..
PR
05/10PROTAGONIST THERAPEUTICS : Announces Data from Phase 2 Rusfertide Study in Hereditary Hemo..
AQ
23/09PROTAGONIST ALERT : Bragar Eagel & Squire, P.C. is Investigating Protagonist on Behalf of ..
BU
20/09PROTAGONIST THERAPEUTICS : Reports FDA Clinical Hold on Rusfertide Clinical Development Pr..
AQ
17/09PROTAGONIST THERAPEUTICS : Reports FDA Clinical Hold on Rusfertide Clinical Development Pr..
PU
17/09PROTAGONIST THERAPEUTICS, INC : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
17/09PROTAGONIST THERAPEUTICS : Reports FDA Clinical Hold on Rusfertide Clinical Development Pr..
PR
15/09PROTAGONIST THERAPEUTICS : Reports Granting of Inducement Awards
PR
07/09PROTAGONIST THERAPEUTICS : Appoints Scott Plevy, M.D., Executive Vice President and Therap..
PR
10/08PROTAGONIST THERAPEUTICS : Announces Resolution of Contract Dispute with Zealand Pharma
PR
10/08PROTAGONIST THERAPEUTICS, INC : Entry into a Material Definitive Agreement (form 8-K)
AQ
04/08PROTAGONIST THERAPEUTICS : Q2 Earnings Snapshot
AQ
04/08PROTAGONIST THERAPEUTICS : Reports Second Quarter 2021 Financial Results and Recent Compan..
PU
04/08PROTAGONIST THERAPEUTICS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND..
AQ
04/08PROTAGONIST THERAPEUTICS : Reports Second Quarter 2021 Financial Results and Recent Compan..
PR
28/07PROTAGONIST THERAPEUTICS, INC : Entry into a Material Definitive Agreement (form 8-K)
AQ
28/07PROTAGONIST THERAPEUTICS : Announces Amendment of Agreement with Janssen Biotech for the C..
PR
30/06PROTAGONIST THERAPEUTICS : Reports Granting of Inducement Award
PR
21/06PROTAGONIST THERAPEUTICS INC. : Announces Closing of $132.2 Million Public Offering of Com..
AQ
18/06PROTAGONIST THERAPEUTICS, INC. : Announces Closing of $132.2 Million Public Offering of Co..
PR
17/06PROTAGONIST THERAPEUTICS, INC : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
16/06PROTAGONIST THERAPEUTICS : Announces Pricing of $115 Million Upsized Public Offering of Co..
PR
14/06PROTAGONIST THERAPEUTICS : Announces Proposed Public Offering of Common Stock
PR
14/06PROTAGONIST THERAPEUTICS, INC : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
14/06PROTAGONIST THERAPEUTICS : Announces Updated Phase 2 Data Supporting Long-Term Efficacy of..
AQ
11/06PROTAGONIST THERAPEUTICS : Announces Updated Phase 2 Data Supporting Long-Term Efficacy of..
PR
07/06PROTAGONIST THERAPEUTICS : to Host Investor Conference Call and Webcast to Discuss Updated..
PR
04/06PROTAGONIST THERAPEUTICS : Receives FDA Breakthrough Therapy Designation for Rusfertide in..
AQ
28/05PROTAGONIST THERAPEUTICS, INC : Submission of Matters to a Vote of Security Holders (form ..
AQ
24/05PROTAGONIST THERAPEUTICS : Announces First Subject Dosed in Phase 1 Study of Oral IL-23 Re..
PR
13/05PROTAGONIST THERAPEUTICS : Announces Presentation of Updated Results from Phase 2 Study of..
AQ
04/05PROTAGONIST THERAPEUTICS : Q1 Earnings Snapshot
AQ
04/05PROTAGONIST THERAPEUTICS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND..
AQ
04/05PROTAGONIST THERAPEUTICS : Reports First Quarter 2021 Financial Results and Provides Corpo..
PR
03/05PROTAGONIST THERAPEUTICS : Reports Granting of Inducement Award
PR
27/04PROTAGONIST THERAPEUTICS : Completes Enrollment for Phase 2 Study of Rusfertide in Polycyt..
PR
23/03PROTAGONIST THERAPEUTICS : Announces Plans to Initiate a Global Phase 3 Study for Rusferti..
AQ
22/03PROTAGONIST THERAPEUTICS : Announces Plans to Initiate a Global Phase 3 Study for Rusferti..
PR
11/03PROTAGONIST THERAPEUTICS : Reports Fourth Quarter and Full Year 2020 Financial Results and..
AQ
10/03PROTAGONIST THERAPEUTICS : Q4 Earnings Snapshot
AQ
10/03PROTAGONIST THERAPEUTICS : Management's Discussion and Analysis of Financial Condition and..
AQ
03/03PROTAGONIST THERAPEUTICS : to Announce Fourth Quarter and Full Year 2020 Financial Results
PR
02/03PROTAGONIST THERAPEUTICS : to Participate in the H.C. Wainwright Global Life Sciences Conf..
PR
01/03PROTAGONIST THERAPEUTICS : Reports Granting of Inducement Award
AQ
27/02PROTAGONIST THERAPEUTICS : Reports Granting of Inducement Award
PR
16/02PROTAGONIST THERAPEUTICS : to Participate in the SVB Leerink Virtual 10th Annual Global He..
PR
01/02PROTAGONIST THERAPEUTICS : Reports Granting of Inducement Award
AQ
30/01PROTAGONIST THERAPEUTICS : Reports Granting of Inducement Award
PR
04/01PROTAGONIST THERAPEUTICS : to Present at the 39th Annual J.P. Morgan Healthcare Conference
PR
2020PROTAGONIST THERAPEUTICS : Announces First Subject Dosed in Phase 1 Study of Oral IL-23 Re..
AQ
2020PROTAGONIST THERAPEUTICS : Announces First Subject Dosed in Phase 1 Study of Oral IL-23 Re..
PR
2020PROTAGONIST THERAPEUTICS, INC. : Announces Closing of $115 Million Public Offering of Comm..
PR
2020PROTAGONIST THERAPEUTICS, INC : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
2020PROTAGONIST THERAPEUTICS, INC. : Announces Pricing of $100 Million Public Offering of Comm..
PR
2020PROTAGONIST THERAPEUTICS, INC. : Announces Proposed Public Offering of Common Stock
PR
2020PROTAGONIST THERAPEUTICS : Announces Results of Large-Scale Analysis of Current Treatment ..
AQ
2020PROTAGONIST THERAPEUTICS : Announces Updated Phase 2 Data Presented at ASH Annual Meeting ..
AQ
2020PROTAGONIST THERAPEUTICS : Hepcidin Mimetic Candidate PTG-300 Receives Fast Track Designat..
AQ
2020PROTAGONIST THERAPEUTICS : Hepcidin Mimetic Candidate PTG-300 Receives Fast Track Designat..
PR
2020PROTAGONIST THERAPEUTICS : Reports Granting of Inducement Award
PR
2020PROTAGONIST THERAPEUTICS : to Host Conference Call and Webcast to Provide a Research Updat..
PR
2020PROTAGONIST THERAPEUTICS : to Present at the Virtual Piper Sandler 32nd Annual Healthcare ..
AQ
2020PROTAGONIST THERAPEUTICS : to Present at the Virtual Piper Sandler 32nd Annual Healthcare ..
PR
2020PROTAGONIST THERAPEUTICS : to Participate in the Jefferies Virtual 2020 London Healthcare ..
PR
2020PROTAGONIST THERAPEUTICS : Reports Third Quarter Financial Results and Provides Corporate ..
AQ
1  2  3Volgende
Volgende evenement op PROTAGONIST THERAPEUTICS, INC.